US OptionsDetailed Quotes
BCLI241115P2000
- 1.50
- 0.000.00%
15min DelayClose Sep 30 16:00 ET
0.00High0.00Low
0.00Open1.50Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV58.68%PremiumNov 15, 2024Expiry Date0.79Intrinsic Value100Multiplier-1DDays to Expiry0.71Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.81Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Brainstorm Cell Therapeutics Stock Discussion
PR Newswire· 3 mins ago
Memorandum of Understanding has been signed
NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly o...
28/10/2024 - 18:00
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenera...
5 MINUTES AGO, 6:00 AM EDT
VIA PR NEWSWIRE
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
No comment yet